- Report
- December 2024
- 436 Pages
Global
From €3527EUR$4,000USD£3,075GBP
- Report
- August 2024
- 62 Pages
Global
From €3967EUR$4,500USD£3,460GBP
- Report
- August 2024
- 112 Pages
Global
From €3967EUR$4,500USD£3,460GBP
- Report
- November 2022
- 150 Pages
Global
From €4276EUR$4,850USD£3,729GBP
- Report
- July 2024
- 91 Pages
Global
From €3500EUR$4,253USD£3,159GBP
- Report
- November 2023
- 87 Pages
Global
From €3500EUR$4,253USD£3,159GBP
- Report
- November 2023
- 125 Pages
Global
From €3500EUR$4,253USD£3,159GBP
- Report
- November 2025
- 132 Pages
Global
From €838EUR$950USD£730GBP
- Report
- January 2025
- 132 Pages
Global
From €838EUR$950USD£730GBP
- Report
- January 2025
- 132 Pages
Global
From €838EUR$950USD£730GBP
- Report
- January 2025
- 132 Pages
Global
From €838EUR$950USD£730GBP
- Report
- July 2024
- 132 Pages
Global
From €838EUR$950USD£730GBP
- Book
- January 2023
- 200 Pages
- Book
- November 2011
Global
- Report
- November 2021
- 1032 Pages
Global
From €4408EUR$5,000USD£3,844GBP

A diagnostic biomarker is a biological molecule or gene that is used to identify a particular disease or condition. It is used to diagnose, monitor, and predict the progression of a disease or condition. Diagnostic biomarkers are used to detect the presence of a disease or condition, to determine the severity of the disease or condition, and to monitor the effectiveness of treatments. Diagnostic biomarkers are used in a variety of medical fields, including oncology, neurology, cardiology, and infectious diseases.
Diagnostic biomarkers are typically identified through a variety of methods, including genetic sequencing, proteomics, and metabolomics. These methods allow for the identification of biomarkers that are specific to a particular disease or condition.
The diagnostic biomarker market is a rapidly growing field, with many companies developing and marketing diagnostic biomarkers. Companies in this market include Illumina, Thermo Fisher Scientific, Qiagen, Roche, and Agilent Technologies. Show Less Read more